FAQ

Preci supplies organ-specific primary cells (liver, kidney, intestine, lung, skin, brain, endothelial), patient-derived tumor cells, cancer-associated fibroblasts (CAFs), peripheral blood mononuclear cells (PBMCs), and immune cell populations. Products are available fresh or cryopreserved and are designed for translational and preclinical research applications including ADMET, oncology, immunology, and metabolic disease modeling. All materials are supplied for research use only.

Preci offers extracellular matrix (ECM)-embedded spheroids, patient-derived tumor cultures, co-culture systems combining epithelial, stromal, and immune cells, and hydrogel-based scaffolds derived from human ECM. All platforms are compatible with high-content imaging systems, automated drug screening workflows, long-term culture, and mechanistic studies. Model configuration can be customized to match specific disease contexts or research pipeline requirements.

ECM-embedded spheroids and hydrogel-based microtissues supplied by Preci are formatted for standard multiwell plate readers and high-content imaging (HCI) systems including confocal, widefield, and spinning-disk configurations. Models are produced in formats compatible with 96- and 384-well plates. Specific dimensional parameters and embedding conditions can be adjusted upon request.

For ADMET applications, Preci provides organ-specific primary cells from liver, kidney, intestine, lung, skin, brain, and endothelial sources. These support predictive pharmacokinetic (PK), drug metabolism, and toxicity studies, including multi-cellular and co-culture models. Human ECM preparations matched to specific organ environments are also available to improve physiological relevance. Contact us to discuss your specific assay requirements.

Yes. Preci supplies patient-derived immune cells including PBMCs, T cells, NK cells, and macrophages. These can be integrated with tumor or stromal products for functional assays including cytotoxicity testing, cytokine profiling, and checkpoint inhibitor evaluation. Donor-matched immune-tumor co-culture configurations are available upon request.

Yes. Preci can supply non-catalog materials including rare tissue types, donor-specific subcellular fractions, and tailored ECM preparations. Availability depends on donor program status and collection site capacity. Contact our team with your specifications to assess feasibility and timelines.

Yes. Custom donor profiling is available across parameters including age, sex, BMI, disease status (e.g., NASH, type 2 diabetes, specific oncology indications), treatment history, and comorbidities. Matched donor cohorts for longitudinal or multi-condition studies can be discussed. Please contact us to outline your program requirements.

Yes. Preci supports development of customized in vitro workflows including mechanistic studies, drug screening strategies, biomarker validation panels, and functional readouts relevant to oncology, metabolism, and inflammation. Our team can advise on experimental design, appropriate cell systems, and assay endpoints from project initiation.

Each Certificate of Analysis (CoA) includes: total cell count, post-thaw viability percentage, purity marker profile confirmed by flow cytometry, sterility test results, mycoplasma testing results, and functional assay data where applicable. ECM-based products include protein quantification data. Batch number and donor traceability information are included on all CoA documents. Example CoA documents are available upon request.

Cryopreserved primary cells and patient-derived products are released with a minimum post-thaw viability of ≥70%, confirmed by trypan blue exclusion or equivalent. Many product categories exceed this threshold. Viability data from the specific lot is reported on the accompanying Certificate of Analysis. Thawing protocol recommendations are included with each shipment.

Preci products are produced under Good Tissue Practice (GTP)-aligned procedures for human biosample handling, isolation, and cryopreservation. Products are intended for research use only and are not manufactured under Good Manufacturing Practice (GMP) certification. If your project requires GMP-grade materials, please contact us to discuss available options.

Batch consistency is maintained through standardized donor screening, cell isolation protocols, and quality release criteria applied uniformly across lots. Each batch undergoes viability assessment, purity confirmation, and functional testing before release.

Yes. All collection, storage, use, and disposal of human biosamples and associated data are conducted under current approvals from independent Ethics Committees (ECs) or Institutional Review Boards (IRBs). Preci’s procedures comply with applicable Ukrainian regulatory frameworks and the EU Tissues and Cells Directive (2004/23/EC). Approval documentation can be provided upon request. See our Ethics & Responsible Research page for further detail.

Yes. All human biological materials supplied by Preci are collected under documented informed consent covering the intended research use. Consent processes comply with the EU Tissues and Cells Directive (2004/23/EC) and applicable Ukrainian bioethics regulations. No materials are collected or supplied without prior EC or IRB approval of the consent framework.

Donor identity is protected through anonymization prior to any data transfer or sample dispatch. Preci’s data handling procedures comply with the General Data Protection Regulation (GDPR) and applicable Ukrainian data protection law. Clinical metadata supplied with samples is de-identified and provided only under a data use agreement. Further information is available on our Ethics & Responsible Research page.

Cryopreserved products must be stored at −150°C to −196°C (liquid nitrogen vapor phase) upon receipt. Short-term storage at −80°C is permissible for up to 72 hours during transit contingency only and is not recommended for long-term inventory. Shelf life at recommended storage conditions is a minimum of 12 months from the date of cryopreservation. Thawing and handling protocols are provided with each product shipment.

To request a quote or place an order, contact us at hi@preci.care or use the contact form on our website. Please include the product name or description, required quantity, intended application, and any donor characteristic requirements. Our team will respond within 2 business days with availability, pricing, and estimated lead time.

Minimum order quantities vary by product category and are confirmed at the time of quote. Custom or donor-specific programs may have volume requirements, which are agreed individually. Contact us to discuss your project scope.

We understand that committing to a first order requires confidence in product performance. If you are evaluating Preci materials for a new application or pipeline, contact us to discuss your requirements — we will work with you to identify the most practical path to validation.

All Preci products are supplied for research use only (RUO). Use in commercial drug development workflows, IND-enabling studies, or clinical trials requires separate evaluation of applicable regulatory requirements. If your project involves such applications, contact us to discuss material specifications and documentation that may support your regulatory needs.

Preci ships to research institutions and commercial laboratories worldwide, including the European Union, United Kingdom, United States, China, India, and other countries. Export of human biological samples (HBS) is conducted in compliance with applicable Ukrainian export regulations and the import requirements of the destination country. Documentation requirements vary by region and are confirmed at the time of order. Contact us to discuss shipping feasibility and required paperwork for your location.

For in-stock catalog products: 7–14 business days, subject to shipping route and customs clearance. For custom or donor-specific orders: lead times are confirmed at the time of project agreement and typically range from 4 to 12 weeks depending on collection requirements. Estimated timelines are confirmed in writing at the time of order.

Yes. Preci ships human biological samples (HBS) using ADR-compliant land transport (ADR = European Agreement Concerning the International Carriage of Dangerous Goods by Road) and temperature-controlled World Courier shipments for international routes. Compliance with ICAO (International Civil Aviation Organization) regulations for air transport of biological substances has been validated through Preci’s logistics partner. Transport documentation is provided with each shipment.

All cryopreserved products are shipped in validated dry shipper dewars maintaining ≤−150°C for the duration of transit. Ambient and refrigerated products are shipped in validated temperature-controlled packaging with continuous data logging where required. Temperature records are available upon request.

Yes. Preci provides technical support at all stages, including experimental design consultation, product handling guidance, thawing and seeding protocols, troubleshooting, and interpretation of quality data. Support is available by email at hi@preci.care and by scheduled call for active project accounts.

Preci combines three capabilities rarely available from a single supplier: (1) proprietary human ECM technology enabling physiologically accurate 3D culture environments derived from human tissue; (2) access to patient-derived materials from a clinical network including rare disease indications and matched immune-tumor sample sets; and (3) direct engagement on custom project design, from donor profiling through assay development. Preci is headquartered in Ukraine with access to a pan-European donor network, enabling competitive lead times for European research institutions. See Preci as a Supplier for full capability overview.